Active Surveillance for Low Risk Prostate Cancer by Lawrence Klotz

Dr. Laurence Klotz, a leading expert in the field, has extensively contributed to the understanding and development of active surveillance (AS) for low-risk prostate cancer. His work emphasizes the importance of careful patient selection based on factors such as Gleason Grade (GG) and other clinical, genetic, and imaging markers to determine the appropriateness of AS​. Active surveillance is now considered a standard care approach for men with low-risk GG1 prostate cancer. This approach minimizes unnecessary treatment while closely monitoring the disease to ensure timely intervention if necessary. The adoption of AS is supported by international professional organizations and is based on a growing body of evidence that indicates a very low risk of prostate cancer-specific mortality for men with GG1 over a 10-year period​. However, there are challenges and considerations that impact the adoption of AS. Clinical barriers such as tumor pathology and patient age are significant. For instance, while AS is widely considered appropriate for men with Gleason 6 disease, there is caution among clinicians, particularly regarding younger patients or those with potential intermediate-risk disease, due to concerns about long-term outcomes and the progression of the disease​. In summary, while AS is a promising strategy for managing low-risk prostate cancer, it requires careful implementation and continuous refinement based on emerging research and clinical data to optimize patient outcomes.